NASDAQ:ESTA News 18 December 2025 - 2 February 2026

Establishment Labs shares rose 5.7% to $72.02 in Monday afternoon trading after hitting $73.77. The company forecasted 2025 revenue between $210.5 million and $211.5 million, with a February earnings call set for full results. FDA review of Motiva implants for breast reconstruction is pending. The stock is up about 11% since Jan. 27.

Establishment Labs shares fell about 5% to $69.22 in early Friday trading, reversing part of a 10% gain earlier in the week. The drop came as broader U.S. markets rose on a softer December jobs report. Investors are watching for updates at the company’s Jan. 14 J.P. Morgan Healthcare Conference presentation and awaiting FDA review of its Motiva breast implants.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has become one of the more closely watched mid-cap medtech stories of late 2025—surging to new highs this week, then snapping back sharply on Thursday, December 18. Shares of Establishment Labs ended the day at $70.01, down about 6.3%, after trading in a wide intraday range between $69.74 and $76.02. That pullback follows a powerful multi-session run that pushed the stock to fresh peaks earlier this week, including an intraday high of $78.24 on December 17. StockAnalysis The timing matters: the decline hit just as Wall Street price targets have been moving higher and